A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma

Author(s): Madan M. Kwatra

Journal Name: Current Cancer Drug Targets

Volume 17 , Issue 3 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Glioblastoma (GBM) is a deadly brain cancer, and all attempts to control it have failed so far. However, the future looks bright, as we now know the molecular landscape of GBM through the work of The Cancer Genome Atlas (TCGA) program. GBMs exhibit significant inter- and intratumoral heterogeneity, and to control this type of tumor, a personalized approach is required. One target, whose gene is amplified and mutated in a large number of GBMs, is the epidermal growth factor receptor (EGFR). But all attempts to target it have been unsuccessful. We attribute the reason for this failure to the molecular heterogeneity of EGFR in GBM, as well as to the poor brain penetration of previously tested EGFR-Tyrosine Kinase Inhibitors (EGFR-TKIs). In this review, we discuss the molecular heterogeneity of EGFR and provide rational preclinical and clinical guidelines for testing AZD9291, a third generation, irreversible EGFR-TKI with both a high affinity for EGFRvIII and excellent brain penetration.

Keywords: Glioblastoma, EGFR, heterogeneity, targeted, therapies, TCGA.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 31 January, 2017
Page: [290 - 296]
Pages: 7
DOI: 10.2174/1568009616666161227091522
Price: $65

Article Metrics

PDF: 50
PRC: 1